Evidence map›Paper›PMID 41725045›Full record

ArticleMolecular oncology2026

Pre-analytical optimization of cell-free DNA and extracellular vesicle-derived DNA for mutation detection in liquid biopsies.

Jonas Dohmen, Lucrezia De Santis, Bret M Stephens, Vincent Bernard, Jörg C Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra and 2 more

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jonas DohmenDepartment of Surgery, University of Bonn, Germany.ORCID 0000-0002-6907-3844
Lucrezia De SantisDepartment of Surgery, University of Bonn, Germany.
Bret M StephensSheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vincent BernardSheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jörg C KalffDepartment of Surgery, University of Bonn, Germany.
Lara BraunDepartment of Surgery, University of Bonn, Germany.
Phillipp LeyendeckerDepartment of Surgery, University of Bonn, Germany.
Johannes RöttgenDepartment of Surgery, University of Bonn, Germany.
Daniel WeissingerDepartment of Surgery, University of Bonn, Germany.
Anirban MaitraSheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paola A GuerreroSheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexander SemaanDepartment of Surgery, University of Bonn, Germany.ORCID 0000-0001-5424-3217

Funding

Clinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5M
PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education)U24CA274274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI J. Jack LEE, ANIRBAN MAITRA · 2022 to 2026
$4.9M
Wnt/?-catenin Signaling in Pancreatic OncogenesisR01CA220236 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2017 to 2023
$1.8M
BONFOR B-487.0012BONFOR O-112.0070Break Through CancerBundesministerium für Bildung und Forschung 01EO2107Deutsche Krebshilfe 70117114MD Anderson Pancreatic Cancer Moon Shot ProgramNCI NIH HHS R01 CA220236NCI NIH HHS U01 CA200468NCI NIH HHS U24 CA274274NCI NIH HHS U54 CA274371NIH HHS R01CA220236NIH HHS U01CA200468NIH HHS U24CA274274NIH HHS U54CA274371Sheikh Khalifa Bin Zayed Al-Nahyan Foundation
6 · The paper itself

Abstract

Liquid biopsies enable noninvasive tumor profiling and longitudinal disease monitoring. Their analytical performance is strongly influenced by pre-analytical factors, yet direct comparisons between cell-free DNA (cfDNA) and extracellular vesicle-derived DNA (evDNA) remain scarce. We prospectively evaluated four pre-analytical variables: processing delay, storage temperature, tube type, and plasma input volume, on cfDNA and evDNA from cancer patient plasma (n = 244) using ddPCR, Qubit, and TapeStation. Key findings were validated in archived plasma samples (n = 723). In the prospective cohort, cfDNA concentrations increased after 24 h and evDNA after 48 h at room temperature, while retrospective analysis revealed earlier changes (cfDNA: 6 h; evDNA: 24 h). Storage conditions influenced both analytes, as short-term refrigeration (4 °C) better preserved DNA quality than -80 °C freezing, while extracted DNA remained stable at -80 °C. Acid citrate dextrose (ACD) and K

Indexed as

Cell-Free Nucleic AcidsExtracellular VesiclesMutationNeoplasmsDNA Mutational AnalysisHumansLiquid BiopsyTemperatureCell-Free Nucleic Acidscell‐free DNA (cfDNA)digital droplet PCR (ddPCR)extracellular vesicle‐derived DNA (evDNA)liquid biopsyplasma biomarkerspre‐analytical variables

Identifiers

PMID41725045
PMCPMC13352965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.